SG11202111221YA - Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) - Google Patents
Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1)Info
- Publication number
- SG11202111221YA SG11202111221YA SG11202111221YA SG11202111221YA SG11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA SG 11202111221Y A SG11202111221Y A SG 11202111221YA
- Authority
- SG
- Singapore
- Prior art keywords
- p27kip1
- small molecules
- kinase inhibitor
- dependent kinase
- bind cyclin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817924P | 2019-03-13 | 2019-03-13 | |
| PCT/US2020/022475 WO2020186110A1 (en) | 2019-03-13 | 2020-03-12 | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111221YA true SG11202111221YA (en) | 2021-11-29 |
Family
ID=72427117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111221YA SG11202111221YA (en) | 2019-03-13 | 2020-03-12 | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220177457A1 (en) |
| EP (1) | EP3937926A4 (en) |
| KR (1) | KR20210150411A (en) |
| CN (1) | CN113825506A (en) |
| AU (1) | AU2020235112A1 (en) |
| CA (1) | CA3136242A1 (en) |
| SG (1) | SG11202111221YA (en) |
| WO (1) | WO2020186110A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336735B (en) * | 2021-06-08 | 2022-09-30 | 常州大学 | Urolithin compound, preparation method, pharmaceutical composition and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007101247A2 (en) * | 2006-02-28 | 2007-09-07 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| WO2007127263A2 (en) * | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Therapeutic uses of urolithins |
| BRPI0909374A2 (en) * | 2008-03-25 | 2015-10-06 | Paloma Pharmaceuticals Inc | Methods to Treat Fibrotic Disorders |
| EP2594555B1 (en) * | 2010-07-02 | 2018-03-07 | ASKA Pharmaceutical Co., Ltd. | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR |
| WO2015100213A2 (en) * | 2013-12-23 | 2015-07-02 | Amazentis Sa | Process-scale synthesis of urolithins |
-
2020
- 2020-03-12 CN CN202080033970.5A patent/CN113825506A/en active Pending
- 2020-03-12 CA CA3136242A patent/CA3136242A1/en active Pending
- 2020-03-12 AU AU2020235112A patent/AU2020235112A1/en not_active Abandoned
- 2020-03-12 US US17/438,857 patent/US20220177457A1/en active Pending
- 2020-03-12 WO PCT/US2020/022475 patent/WO2020186110A1/en unknown
- 2020-03-12 KR KR1020217032892A patent/KR20210150411A/en unknown
- 2020-03-12 SG SG11202111221YA patent/SG11202111221YA/en unknown
- 2020-03-12 EP EP20769404.3A patent/EP3937926A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3937926A4 (en) | 2022-12-14 |
| CN113825506A (en) | 2021-12-21 |
| AU2020235112A1 (en) | 2021-11-04 |
| AU2020235112A8 (en) | 2021-12-09 |
| EP3937926A1 (en) | 2022-01-19 |
| CA3136242A1 (en) | 2020-09-17 |
| KR20210150411A (en) | 2021-12-10 |
| US20220177457A1 (en) | 2022-06-09 |
| WO2020186110A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282928A (en) | Vaporizing related data protocols | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| PL3305788T3 (en) | Janus kinase inhibitor | |
| SG11202105515WA (en) | Proof-of-work for blockchain applications | |
| EP3902805A4 (en) | Cyclin-dependent kinase inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL275207A (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP3804707A4 (en) | Kinase inhibitor | |
| EP3613737A4 (en) | Novel inhibitor of cyclin-dependent kinase cdk9 | |
| GB201819126D0 (en) | Inhibitor compounds | |
| EP3641776C0 (en) | Atropisomerism for enhanced kinase inhibitor selectivity | |
| ZA202102261B (en) | Spak kinase inhibitors as neuroprotective agents | |
| SG11202008705TA (en) | Heteroaryl compounds as kinase inhibitor | |
| EP3902801A4 (en) | Cyclin-dependent kinase inhibitors | |
| IL292799A (en) | Anti-siglec-9 antibody molecules | |
| SG11202111221YA (en) | Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1) | |
| ZA201904554B (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| ZAF201801269S (en) | Chassis | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201805450D0 (en) | Movable chassis | |
| ZAA201801287S (en) | Instrument board |